



The
**Patent
Office**

PCT/GB 98 / 02820

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales

NP9 1RH REC'D 07 OCT 1998

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Dated 28 September 1998



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



200 OCT 97 E310937-1 0002854
801/7700 25.00 - 97221 The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

PHM.97-074 GB/P

2. Patent application number

(The Patent Office will fill in this part)

17 OCT 1997

9722012.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ZENECA Limited
15 Stanhope Gate
LONDON, W1Y 6LN, United Kingdom
Patents ADP number (if you know it)

6254007002
If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

COMPOUNDS

5. Name of your agent (if you have one)

TAIT, Brian Steele
"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

Intellectual Property Department
ZENECA Pharmaceuticals, Mereside,
Alderley Park, Macclesfield
Cheshire, SK10 4TG, United Kingdom
Patents ADP number (if you know it)

5684600002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 21

Claim(s) *J*

Abstract

Drawing(s) 7 + 7

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

JM marshall.

Date

16 OCT 97

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs Joanne Marshall - 01625 516485

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

COMPOUNDS

This invention relates to antisense oligodeoxynucleotides targeted to sequences in thymidylate synthase (TS) mRNA. In particular the invention relates to antisense 5 oligodeoxynucleotides targeted to sequences in the 3' end of TS mRNA, which antisense oligodeoxynucleotides are both cytostatic on their own when administered to human tumour cell lines, and also enhance the toxicity of the anticancer drugs such as Tomudex administered to those cells. In contrast, antisense oligodeoxynucleotides targeted to sequences at or near the translation start site at the 5' end of TS mRNA have either no effect, or enhance cell 10 growth, when administered on their own. In addition, antisense nucleic acids targeted to these 5' sequences (but not to 3' sequences) induce TS gene transcription. The invention also relates to a combination product comprising an antisense oligodeoxynucleotide in combination with an anticancer agent such as Tomudex (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) or the Zeneca 15 development compound ZD 9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzamido)-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid), and to the use of such a combination product in the treatment of cancer.

Thymidylate synthase (TS) (EC 2.1.1.45) catalyses the conversion of deoxyuridylate

20 to thymidylate, and is a housekeeping enzyme essential for the only intracellular *de novo* synthesis of thymidylate (Danenberg, 1977). TS gene expression is tightly regulated with respect to cell proliferation state (Maley and Maley, 1960; Lochsin *et al.*, 1979). As such, the TS gene is part of a group of genes whose expression is elevated at the G₁/S cell cycle boundary, and it has been suggested that transcription of several S-phase genes (including 25 dihydrofolate reductase and thymidine kinase) is controlled in part by the E2F family of transcription factors (Farnham *et al.*, 1993; Mudrak *et al.*, 1994). In fact, transfection of active E2F1 genes into mouse cells induces expression of TS and other S-phase and cell cycle-regulated genes (De Gregori *et al.*, 1995). As cells progress through the cell cycle from G₀ through S phase, TS mRNA levels increase approximately 20-fold and TS enzyme activity 30 increases about 10-fold (Navalgund *et al.*, 1980). However, TS gene transcription rate is upregulated only 2 to 4 times, suggesting that post-transcriptional events play a major role in TS regulation (Ayusawa *et al.*, 1986; Jenh *et al.*, 1985; Johnson, 1994). Differences in TS

mRNA stability are not likely to be critical in regulation, as TS mRNA half-life is about 8 hours in both resting and growing rodent cells (Jenh *et al.*, 1985). On the other hand, TS mRNA translation appears to be regulated by the TS protein itself, which specifically interacts at two sites within its own mRNA to inhibit protein production (Chu *et al.*, 1991, 1993b, 5 1994; Voeller *et al.*, 1995). Translation of other mRNAs (including *c-myc* mRNA) may also be regulated by interactions with TS protein (Chu *et al.*, 1995).

Because of its role in DNA precursor synthesis, TS has been identified as a potential target for cancer chemotherapeutic agents (Hardy *et al.*, 1987). High TS levels have been 10 correlated with poor prognosis in patients with ovarian cancer (Suzuki *et al.*, 1994), rectal cancer (Johnston *et al.*, 1994) childhood acute non-lymphoblastic leukaemia (Volm *et al.*, 1994), and non-small cell lung carcinoma (Volm and Mattern, 1992). However, its prognostic value is not high in all tumour types (Peters *et al.*, 1986, 1994). Two types of TS inhibitors 15 have been developed: (a) nucleotide analogues (including 5-FU, its riboside, and deoxyriboside derivatives) which must be activated to 5-fluorodeoxyuridylate (FdUMP) within cells to be effective (Heidelberger *et al.*, 1983) and (b) 5,10-CH₂FH₄ (antifolate) analogues, including *N*-10-propargyl-5,8-dideazafolate (CB3717) (Calvert *et al.*, 1986) and Tomudex (ZD1694; *N*-[5-(*N*-[3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl]-*N*-methylamino)-2-thenoyl]-L-glutamic acid) (Jackman *et al.*, 1991a, 1991b). Although 20 ~~Tomudex and 5-FU inhibit TS and have potent cytotoxic and antitumour activity~~ (Heidelberger *et al.*, 1983; Keyomarsi *et al.*, 1993), they have an unusual biochemical effect. When human cancer cell lines are treated with 5-FU or Tomudex, TS levels increase rapidly, perhaps as a result of the release of translational inhibition by the TS protein (Keyomarsi *et al.*, 1993; Chu *et al.*, 1990; Chu *et al.*, 1993a).

25

It has been speculated that the release of translational inhibition that accompanies binding and inactivation of TS by chemotherapeutic agents (including Tomudex and 5-FU) might be prevented by treating cells with agents that could replace the specific interaction between TS mRNA and TS protein, and inhibit translation (Keyomarsi *et al.*, 1993) but no 30 such agents were described. In another speculative article it was hypothesised that antisense nucleic acids designed to both reduce the ability of TS mRNA to direct protein production,

d to interact with the TS protein binding site, may be useful in complementing the effectiveness of drugs targeted against TS (Rapaport *et al.*, 1992).

To this end we attempted to specifically down-regulate the expression of TS in human
5 breast cancer (MCF-7) cells in two ways. First, we both transiently and stably transfected the
cells with vectors expressing antisense RNA molecules directed to hybridise to three different
regions of the TS mRNA. Targeted sequences were: (1) sequences participating in the
formation of a putative stem-loop structure surrounding the translation start site, and
immediately adjacent and 3' to that site (these sequences also participate in binding TS
10 protein to modulate translation), (2) the exon1/exon2 boundary and (3) the 3' end of the
mature cytoplasmic mRNA. Antisense TS RNA was expressed from these vectors (as
assessed by northern blot analysis and a novel modification of the run-on transcription assay
to measure antisense transcription against background constitutive TS gene expression)
(Koropatnick *et al.*, 1997). Second, we transiently transfected cells with single-stranded
15 oligodeoxynucleotides targeted to hybridise to: (a) the translation start site and sequences
surrounding it, (b) a sequence proximal to the translation start site and participating in the
putative stem-loop structure, and (c) the translation stop site near the 3' end of the mature
cytoplasmic RNA.

20 The present invention is based on our discovery that antisense oligonucleotides
targeted to different mRNA sequences can inhibit, enhance, or have no effect on thymidylate
synthase activity and tumour cell growth. Furthermore, transcription of constitutive TS gene
expression is stimulated in response to antisense RNA and oligonucleotides directed toward
sequences at or near the mRNA translation start site, but not in response to sequences within
25 the coding region or at and surrounding the translation stop signal.

In a first aspect of the invention we provide an antisense oligodeoxynucleotide which
hybridises to a target nucleic acid sequence in thymidylate synthase and which selectively
inhibits thymidylate synthase production in mammalian cells. Preferably the oligonucleotide
30 is targeted to sequences at or near the translational stop site at the 3' end of the TS gene,
which sequences lie in the region between bases 800 and 1600, using the sequence numbering
described for human thymidylate synthase mRNA by Takeishi *et al.*, 1985. More preferably

the sequences lie in the region between bases 1000 and 1530. Most preferably the sequences lie in the region between bases 1030 and 1460.

In a second aspect of the invention we provide an antisense oligodeoxynucleotide
5 which hybridises to a target nucleic acid sequence in thymidylate synthase and which selectively enhances thymidylate synthase production in mammalian cells. Preferably the oligonucleotide is targeted to sequences at or near the translation start site at the 5' end of the TS gene, which sequences lie in the region between bases 1 and 300, using the sequence numbering in Takeishi *et al.*, 1985. More preferably the sequences lie in the region between
10 bases 50 and 200. Most preferably the sequences lie in the region between bases 90 and 130.

An antisense oligodeoxynucleotide is an oligonucleotide which is designed to hybridise to a specific region of a target nucleic acid sequence. The target nucleic acid is the TS gene or mRNA transcribed from the TS gene. Preferably the target nucleic acid is the
15 mRNA encoding thymidylate synthase.

The effects of antisense oligonucleotides on thymidylate synthase expression can be measured using procedures which are well known to persons skilled in the art. In the present application, effects on mRNA levels have been measured by Northern blot analysis and
20 ~~nuclear run-on transcription assay, and effects on the growth of human tumour cells have been~~ measured by counting cell numbers using a Coulter counter.

Antisense oligonucleotides to thymidylate synthase may inhibit, stimulate or have no effect on thymidylate synthase expression. Of these, preferred antisense oligonucleotides are
25 those which either inhibit or stimulate thymidylate synthase expression, and particularly preferred antisense oligonucleotides are those which inhibit thymidylate synthase expression.

By inhibition of thymidylate synthase expression we mean inhibition of at least 10% relative to the untreated control, measured at day 4 using the assay described in Example 1.2.
30 Preferably inhibition of thymidylate synthase expression is at least 20% and most preferably inhibition is at least 40%.

By stimulation of thymidylate synthase expression we mean stimulation of at least 10% relative to the untreated control, when measured at day 7 using the assay described in Example 1.2. Preferably stimulation is at least 20% and most preferably stimulation is at least 40%.

5

Preferably, the antisense oligonucleotides are from about 8 to about 50 nucleotides in length, more preferably from about 12 to about 40 nucleotides in length and most preferably from about 16 to about 30 nucleotides in length.

10 Specific examples of sequences of antisense oligonucleotides which regulate thymidylate synthase activity are shown in Table 1. The regions of TS mRNA targeted by the oligonucleotides are shown in Figure 7.

Table 1:

15

ANTISENSE OLIGONUCLEOTIDE	SEQUENCE
OLIGO 83	TTAAGGATGTTGCCACTGGC
OLIGO 86	AATGGCTGTTAGGGTGCTT
OLIGO 90	TGTGGCCGGCTCGGAGCTGC
OLIGO 91	GCGCCATGCCTGTGGCCGGC
OLIGO 92	GCGCCATGCCTGTGGCCGGC
OLIGO 93	CCCGCCCCGCCGCCATGCC

It will be appreciated that the invention is not restricted merely to those specific antisense oligonucleotides which are disclosed in Table 1 above but encompass 20 oligonucleotides of from about 8 to about 50 nucleotides in length which selectively inhibit or selectively enhance thymidylate synthase production and which are selected from those regions of the TS gene which are described hereinbefore.

25 Hybridisation of an antisense oligonucleotide to its target nucleic acid sequence is mediated by the formation of hydrogen bonds between complementary bases on each nucleic

acid strand. Hybridisation may occur between nucleic acid strands which have varying degrees of complementarity, depending on the hybridisation conditions employed. The term "specifically hybridisable" is used to describe an oligonucleotide which has a sufficient degree of complementarity to ensure stable, specific binding to its target sequence, whilst 5 avoiding non-specific binding to non-target sequences.

10 Antisense oligonucleotides may be designed to hybridise to any region within the thymidylate synthase mRNA molecule, including the coding region, the 5' untranslated region, the 3' untranslated region, the 5' cap region, introns and intron/exon splice junctions.

15 Hybridisation of the antisense oligonucleotide to thymidylate synthase mRNA may affect any aspect of mRNA function, for example mRNA translocation, mRNA splicing, mRNA translation, or the feedback inhibition mechanism regulated by the binding of thymidylate synthase protein to binding sites within the thymidylate synthase mRNA molecule.

20 An oligonucleotide is a polymeric molecule which is assembled from nucleotide or nucleoside monomers. The monomers may consist of naturally occurring bases, sugars and inter-sugar linkages or may also contain non-naturally occurring derivatives which modify the properties of the oligonucleotide, for example, phosphorothiorated oligonucleotides have been used in the present application to increase resistance to nuclease degradation.

25 Preferred oligonucleotides may contain phosphorothiorates, phosphotriesters, methyl phosphonates or short chain alkyl, cycloalkyl or heteroatomic intersugar linkages. Other preferred oligonucleotides may contain a peptide nucleic acid backbone. Particularly preferred oligonucleotides are those containing phosphorothiorates (Summerton, J.E. and Weller, D.D., U.S. Patent No: 5,034,506).

30 The oligonucleotides may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition.

In a further aspect of the present invention, there is provided a combination product comprising an antisense oligonucleotide targeted to thymidylate synthase in combination with an anticancer agent. The antisense oligonucleotide and the anticancer agent may be 5 administered separately, sequentially, simultaneously or in a mixture.

The anticancer agent may cover three main categories of therapeutic agent:

(i) thymidylate synthase inhibitors such as Tomudex (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) (European Patent Application no. 0239362, Example 7, compound no. 8 therein); Zeneca development compound ZD9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzamido)-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid) (European Patent Application no. 0562734, Example 3 thereof); LY 231514 (Eli Lilly Research Labs, Indianapolis, IN); 1843U89 (Glaxo-Wellcome, Research Triangle Park, NC); AG337 and AG331 (both by Agouron, La Jolla, CA) (Touroutoglou and Pazdur, Clin. Cancer Res., 2, 227-243, 1996).

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxitene, iodoxifene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole, exemestane), antiprogesterogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 α -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example EGF, FGFs, platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors).

30

(iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines

like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, 5 chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan).

10 Particularly preferred anticancer agents are thymidylate synthase inhibitors such as Tomudex (N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid) (European Patent Application no. 0239362, Example 7, compound no. 8 therein) and the Zeneca development compound ZD9331 ((S)-2-(2-fluoro-4-[N-(4-hydroxy-2,7-dimethylquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzamido)-4-(1H-15 1,2,3,4-tetrazol-5-yl)butyric acid) (European Patent Application no. 0562734, Example 3 thereof).

20 In a further aspect of the present invention there is provided a pharmaceutical composition comprising a combination product as defined hereinbefore and a pharmaceutically acceptable diluent or carrier.

The pharmaceutical composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example a 25 snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or particularly for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or 30 suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients.

Tomudex is conveniently administered to humans by intravenous injection of a sterile aqueous solution at a dose in the range, for example, of 1 to 4 mg/m² of body surface area once every three weeks, preferably at a dose of 3 mg/m² once every three weeks.

5 ZD 9331 is conveniently dosed to humans by oral administration of a solid dosage form or by intravenous injection of a sterile aqueous solution. The oral dosage form is conveniently administered to humans at a total dose in the range, for example, of about 1 to 100 mg/kg (i.e. about 35 mg/m² to 3.5 g/m²) every three weeks given by a continuous or an intermittent dosing schedule, for example a dosing schedule of a three week dosing cycle

10 comprising daily doses on days 1 to 5 only followed by no further doses until the next dosing cycle or a dosing schedule of a four week dosing cycle comprising daily doses on days 1 to 14 only followed by no further doses until the next dosing cycle. Preferably the oral dosage form is administered to humans at a total dose in the range, for example, of about 1 to 30 mg/kg every three or four week dosing cycle. The sterile aqueous solution is conveniently

15 administered intravenously to humans at a total dose of up to 100 mg/m² every three weeks given by a continuous or an intermittent dosing schedule, for example, a dosing schedule of one dose per three week dosing cycle, a dosing schedule of a three week dosing cycle comprising daily doses on days 1 to 5 only followed by no further doses until the next dosing cycle, a dosing schedule of a three week dosing cycle comprising doses on days 1 and 8 only

20 followed by no further doses until the next dosing cycle or a dosing schedule of a three week dosing cycle comprising continuous infusion on days 1 to 5 followed by no further dosing until the next dosing cycle. Preferably the sterile aqueous solution is administered intravenously to humans at a total dose in the range, for example, of about 20 to 50 mg/m² every three weeks given by a continuous or an intermittent dosing schedule as illustrated

25 hereinbefore.

30 The antisense oligonucleotide is conveniently administered to humans by intravenous injection of a sterile aqueous solution at a dose per dosing cycle in the range, for example, of 0.1 μ g to 1g, preferably at a dose of 1mg to 100mg.

30 The amount of active ingredient that is combined with one or more excipients to produce appropriate dosage forms will necessarily vary depending upon the particular

component of the combination product, the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 μ g to 2g of active agent compounded with appropriate and convenient amounts of excipients which may vary from about 5 to about 98 percent by weight of the total composition. A formulation intended for parenteral administration to humans will generally contain 0.1 μ g to 50mg. Dosage unit forms will generally contain about 1 μ g to about 500mg of an active ingredient.

In a further aspect of the invention there is provided a method for the treatment of cancer (or a method for providing an antiproliferative effect) which comprises administering to a warm-blooded animal an effective amount of a combination product as defined above. The invention also provides the use of such a combination product in the production of a new medicament for the treatment of cancer (or for the treatment of proliferative disease).

Abbreviations used in this application are set out below.

TS	thymidylate synthase
CMV	cytomegalovirus
5-FU	5-fluorouracil
20 PBS	phosphate-buffered saline
GAPDH	glyceraldehyde-3-phosphate-dehydrogenase
FBS	fetal bovine serum
MT	metallothionein
ODN	oligodeoxynucleotide
25 bp	base pairs
DMEM	Dulbecco's modified Eagle medium
oligo	oligonucleotide

The invention will now be illustrated but not limited by reference to the following
30 Example and Figures wherein:

Figure 1 shows that MCF-7 cell growth is inhibited by transfection with antisense TS oligo 86 (targeted to the translation stop site), but is enhanced by transfection with antisense TS oligos 90 or 92 (targeted to sequences at or near the translation start site).

5 *Figure 2* shows that HeLa cell growth is inhibited by transfection with antisense TS oligo 86 (targeted to the translation stop site), but is enhanced after transfection with antisense TS oligo 91 (targeted to the translation start site).

10 *Figure 3* shows that HeLa cell growth is inhibited by transfection with antisense TS oligo 83 (targeted to a 3' untranslated sequence downstream of the translation stop site), but is not affected by transfection with antisense TS oligo 81 (targeted to the translation start site).

15 *Figure 4* shows that transient transfection of HeLa cells with oligo 86 (targeted to the TS translation stop site) enhances sensitivity to Tomudex and that oligo 91 (targeted to the TS translation start site) reduces sensitivity to Tomudex.

20 *Figure 5* shows that transient transfection of HeLa cells with oligo 83 (targeted to a sequence in the 3' untranslated region of TS mRNA) enhances sensitivity to Tomudex whereas oligo 81 (targeted to a 3' sequence downstream of that targeted by oligo 81) has no effect on Tomudex sensitivity.

Figure 6 shows that antisense TS oligo 91, but not oligo 86, stimulates TS gene transcription in human HeLa cells.

25 *Figure 7* shows the sequence of human mRNA for thymidylate synthase (EC 2.1.1.45), bases 1 to 1536.

Example 1**Example 1.1: Experimental Methods**5 **Cell culture:**

MCF-7 (human breast adenocarcinoma) cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 10 mM Hepes (pH 7.4) and 0.1% Gentamycin.

10 **Vector construction:**

Expression vectors pAS/TSS and pAS/exon1,2 were designed to produce, upon transfection into MCF-7 cells, single-stranded antisense RNA molecules containing double-stranded 30 bp oligonucleotides complementary to the TS mRNA at one of two sites.

15 Oligodeoxynucleotides corresponding to each strand of the human TS cDNA at positions 111 to 140 (pAS/TSS; targeting a 30 bp region adjacent to, and 2 bp away from, the translation start site) or 296 to 325 (pAS/exon1,2; targeting a 30 bp region spanning the exon 1/exon 2 boundary) were synthesized. Numbering of bases was according to GenBank accession no. X02308 (Takeishi *et al.*, 1985). In order to facilitate cloning, six additional nucleotides were incorporated (5 at the 5' end, 1 at the 3' end) of each oligodeoxynucleotide to produce *Hind* III or 20 *Xba* I sticky ends when complementary strands were annealed. Single-stranded oligonucleotides (4 mg each) were annealed in 3X SET (450 mM NaCl, 60 mM Tris-HCl, 3 mM EDTA, pH 7.8) by treating the mixture for 5 min at 90°C, 5 h at 50°C, then 16 h at 25°C. Double-stranded products were identified by gel electrophoresis, and directionally inserted into the *Hind* III and *Xba* I sites of pRC/CMV (Invitrogen Corp., San Diego, CA). The orientation of cloning was 25 confirmed by direct sequencing.

Oligodeoxynucleotides:

30 Fully phosphorothioated 20-mer oligonucleotides (ODNs) were synthesized by Isis Pharmaceuticals (Carlsbad, CA). The 6 terminal nucleotides at the 5' and 3' ends of each ODN were 2'-methoxyethoxy-modified to make them resistant to intracellular nucleases and increase their stability within cells (McKay *et al.*, 1996), but the internal 8 nucleotides without methoxyethoxy groups were susceptible to RNase H cleavage. Oligo 86 was complementary to

mRNA from base positions 1035 to 1054 (GenBank accession no. X02308; Takeishi *et al.*, 1985), which surround the TS mRNA translation stop site (UAG at bases 1045 to 1047). Oligo 90 was complementary to base positions 111 to 130, which are 3' and proximal to the translation start site (AUG at bases 106 to 109). Oligo 92 was complementary to base positions 101 to 120, 5 including and surrounding the translation start site.

Transfection:

Antisense RNA expression vectors were transfected into MCF-7 cells using Lipofectamine (GIBCO BRL, Burlington, ON, Canada), a polycationic liposome formulation. 10 1.5 X 10⁶ cells were dispensed into 100 X 15 mm tissue culture plates and allowed to adhere overnight. Cells were washed once with 3 ml OptiMEM (GIBCO BRL, Burlington, ON, Canada), followed by exposure to 6 ml of a mixture of double-stranded expression vector DNA (0.83 µg/ml) plus Lipofectamine (1.67 µg/ml) in opti-MEM for 6 h at 37°C in a 5% CO₂ incubator. The DNA/Lipofectamine mixture was removed and replaced with 10 ml DMEM with 15 supplements. Control cells were transfected with pRC/CMV vector without insert. Transiently-transfected cells were used within 1 to 6 days. Stably-transfected cells were allowed to recover in complete non-selective medium without Geneticin for 48 h, then grown in the presence of Geneticin (400 µg per ml, active form [Gibco/BRL]) to allow selection of colonies harboring pRC/CMV control vectors, or pRC/CMV vectors expressing RNA complementary to sequences 20 surrounding the translation start site (pAS/TSS).

Single-stranded oligodeoxynucleotides (0.5 µM or 1.0 µM) were transiently transfected into 1.5 X 10⁶ MCF-7 cells adhering to 100 X 15 mm tissue culture plates, in a total volume of 5 ml in the presence of Lipofectamine (2 µg/ml) in Opti-MEM. Control cells were treated with 25 Lipofectamine/Opti-MEM without added DNA. Cells were washed after 6 h, medium plus supplements added as described above, and then grown for 48 hours before isolation of nuclei for run-on transcription measurement.

Southern blot analysis:

30 Total DNA was isolated from pAS/TSS transfected cells as follows. Cells were incubated in lysis buffer (50 mM Tris-HCl [pH8.0], 100 mM EDTA, 100 mM NaCl, 1% sodium dodecyl sulfate, 0.5 mg/ml proteinase K) for 6 h at 55°C. One-third the volume of 6 M NaCl was

added to precipitate non-nucleic acids by centrifugation at 10,000 X g for 15 min. The DNA in the supernatant was precipitated in isopropanol and washed with 70% ethanol. DNA was cleaved with *Hind* III for 16 h and analysed by Southern blotting (Sambrook *et al.*, 1989). Blots were hybridized with an [α -³²P]dCTP random primer-labeled pAS/TSS probe (Church and 5 Gilbert, 1984), and were exposed to a phosphor screen and quantitated using a PhosphorImager and the ImageQuant program (Molecular Dynamics, Sunnyvale, CA). The nylon membranes were stripped and rehybridized with an *Alu* probe (300 bp of a human *Alu* restriction fragment inserted into pBR322 [Jelinek *et al.*, 1980]) in order to quantitate the amount of human DNA loaded in each lane (Koropatnick *et al.*, 1988).

10

Northern blot analysis:

RNA was isolated using RNeasy columns (Qiagen Inc., Chatsworth, CA) from cells transfected with the pAS/TSS expression vector. Ten or 15 ug of RNA per lane were separated on a 1.4% formaldehyde gel (Sambrook *et al.*, 1989) and transferred to a Hybond-N nylon 15 membrane. Membranes were hybridized (Church and Gilbert, 1984) with either a pAS/TSS-generated riboprobe (Promega Corp., Madison, WI) designed to bind to antisense RNA, or a random primer-labeled, 1.9 kb *Xho* I fragment from pcHTS-1 (a eukaryotic expression vector containing the human TS cDNA: a generous gift from Dr. K. Takeishi, University of Shizuoka, Shizuoka, Japan)(Takeishi *et al.*, 1985). Blots were stripped and rehybridized with cDNA probes 20 to detect 18S ribosomal RNA or glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Images were quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

Isolation of nuclei:

Relative transcription rates were determined by a nuclear run-on assay (Koropatnick *et* 25 *al.*, 1997), a modification of the methods of Kikuchi *et al.* (1992) and Almendral *et al.* (1988). Nascent transcripts were extended *in vitro* (Marzluff and Huang, 1984) in parallel reactions using MCF-7 cell nuclei isolated 48 h following transient transfection with control or antisense TS RNA expression vectors, or single-stranded antisense TS oligodeoxynucleotides (or 30 Lipofectamine alone), and from cells stably transfected with antisense RNA expression vectors. Adherent cells were rinsed twice with ice-cold PBS, scraped off with a rubber policeman, pelleted in PBS (5 min, 500 X g) and lysed by incubating 5 min at 4° C in 4 ml of lysis buffer (10 mM Tris-Cl, pH 7.4, 10 mM NaCl, 3 mM MgCl₂, 0.5% NP-40). All subsequent steps were

carried out at 4° C. Complete cell lysis and integrity of released nuclei was checked by light microscopy, and nuclei were pelleted by centrifugation at 500Xg for 5 min. Nuclei were then resuspended in 4 ml of lysis buffer by vortexing, pelleted by centrifugation, resuspended in 200 µl of nuclei storage buffer (40% glycerol, 5 mM MgCl₂, 50 mM Tris-HCl [pH 8.0], 0.1 mM 5 EDTA) in a 15 ml conical polypropylene centrifuge tube, and immediately frozen in liquid nitrogen and stored at -120° C until use up to one month later.

Run-on transcription:

RNA elongation reactions were performed for 30 min at 30°C using 2 X 10⁷ nuclei/400 10 µl reaction. Reaction mixtures were composed of 200 µl nuclei storage buffer plus 200 µl of sterile 2X reaction buffer (10 mM Tris-HCl [pH 8.0], 5 mM MgCl₂, 0.3 M KCl, 1 mM ATP, 1 mM CTP, 1 mM GTP, 5 mM dithiothreitol, and 2 µl [α -³²P]UTP or [α -³²P]CTP [\approx 3000 Ci/mmol, 10 mCi/ml]). Nucleotides, radionucleotides, and dithiothreitol were added 15 immediately prior to use. Nascent RNA transcripts were allowed to elongate for 30 min at 30°C on a shaking platform, followed by addition of 600 µl of RNase-free DNase I (0.04 units RQ1 DNase I [RNase-free; Promega Corp.], 0.5 M NaCl, 50 mM MgCl₂, 2 mM CaCl₂, 10 mM Tris-HCl [pH 7.4]). The ³²P-labeled RNA was isolated using Trizol (Gibco/BRL), and the final precipitated RNA was dissolved in Church hybridization buffer (1 mM EDTA, 0.5 M NaHPO₄ [pH 7.2], 7% sodium lauryl sulphate [SLS]), to a final concentration of 4 X 10⁶ cpm per ml.

20

Hybridization of radiolabeled RNA to immobilized unlabeled probes:

In order to distinguish between TS sense and antisense RNA molecules produced in isolated nuclei from transfected cells, target DNA (immobilized on nitrocellulose filters in triplicate dots, 2 µg per dot) consisted of single-stranded synthetic oligonucleotides rather than 25 TS cDNA. Strand-specific oligonucleotide probes were also used to assess levels of human metallothionein-2 (MT-2) mRNA and antisense RNA as positive and negative controls, respectively. Single-stranded oligonucleotides were immobilized on nitrocellulose filters by dissolving in 6XSSC (16 µg per ml) and applying 125 µl per dot using a BioRad dot-blot apparatus. Unlabeled complementary cDNA probes for GAPDH mRNA (Denhardt *et al.*, 1988) 30 and 18S ribosomal RNA (Behrend *et al.*, 1994) were denatured and immobilized on the same nitrocellulose filters (5 µg per dot, triplicate dots) using a previously-described protocol (Koropatnick, 1988). Hybridization of radiolabeled RNA to these dots assessed transcription of

GAPDH and 18S rRNA genes, and acted as internal standards against which to measure change in TS gene transcription. For cells transfected with single-stranded oligonucleotides, TS gene transcription was assessed by hybridization of radiolabeled TS RNA transcripts to immobilized target DNA consisting of a 1.9 kb *Xho* 1 fragment isolated from pCHTS-1.

5

Nitrocellulose filters containing triplicate dots of oligonucleotide and cDNA probes to assess run-on transcription of antisense TS RNA expression vectors, and endogenous TS, MT-2, GAPDH and 18S rRNA genes, were prehybridized in Church buffer for 20 min at 65° C in a Hybaid hybridization chamber. The prehybridization buffer was then removed, 2 mls of radiolabeled RNA resulting from 30 min of run-on transcription in isolated nuclei (in Church hybridization buffer, 4 X 10⁶ cpm per ml) was added, and the filters were hybridized for 48 h at 65° C. The filters were then washed twice at 65°C in posthybridization buffer (40 mM Na₂HPO₄, 1% SDS; 20 min per wash). Posthybridization buffer was removed and 8 ml of RNase A (1 µg per ml in 6XSSC) was added and incubated for 30 min at 37° C to reduce signal from unhybridized radiolabeled RNA. After a final wash in posthybridization buffer (10 min, 37° C) filters were blotted dry and bound radioactivity visualized and quantitated using a phosphorimager and the ImageQuant program (Molecular Dynamics, Sunnyvale, CA). Relative transcription of antisense TS expression vectors, endogenous TS genes, and MT-2 genes was defined as:

20

$$\text{Relative transcription rate} = \frac{\text{(hybridisation signal from gene of interest)}}{\text{(hybridisation signal for GAPDH or 18S rRNA genes)}}$$

25

TS oligonucleotide probes:

Bases in bold-face (below) form part of restriction endonuclease sites, and are not sense or antisense TS sequences. Numbering indicates the distance from the beginning of the transcription start site.

30

TS cDNA nucleotides 111 to 140

sense TS (JK-5): **CTAGATGTGGCCGGCTCGGAGCTGCCGCCGGCCA**

tsisense TS (JK-2): AGCTTGCCGGCGCGGGCAGCTCCGAGGCCGGCACAT

TS cDNA nucleotides 296 to 325

sense TS (JK-3): CTAGAGCTACAGCCTGAGAGATGAATTCCCTCTGCA

5 *antisense TS (JK-4): AGCTTGCAAGAGGAATTCATCTCTCAGGCTGTAGCT*

MT-2 oligonucleotide probes (Karin and Richards, 1982):

Sense and antisense oligonucleotide sequences did not have non-complementary sequences added to the 5' and 3' ends. Numbering indicates the distance from the translation start site.

MT cDNA nucleotides -14 to 6

sense MT: CTCTTCAGCACGCCATGGAT

MT cDNA nucleotides 204 to 223

15 *antisense MT: AGGGTCTACCTTCTTGC*

Example 1.2: Antisense oligodeoxynucleotide targeting regions at or near the translation stop site at the 3' end of the TS gene as a method to inhibit growth of human tumour cells

20

a) A 20-mer antisense oligodeoxynucleotide (oligo 86) targeted to the translation stop site at the 3' end of the thymidylate synthase mRNA is growth inhibitory (cytostatic) in a human breast cancer cell line (MCF-7 cells). Antisense oligonucleotides of the same length (oligos 90 and 92), targeted to regions at or near the translation start site at the 5' end of the

25 TS mRNA, are not cytostatic (Figure 1).

b) A 20-mer antisense oligodeoxynucleotides targeted to the TS mRNA translation start site (oligos 91 and 93) did not inhibit growth of a human cervical carcinoma (HeLa) cell line. In fact, growth was significantly enhanced. Antisense oligodeoxynucleotides targeted to 30 the 3' end of the TS mRNA, including the translation stop site (oligo 86) or a sequence in the 3' untranslated region (oligo 83) significantly inhibited HeLa cell growth. An antisense TS

oligonucleotide targeted to another sequence in the 3' untranslated region of TS mRNA (ol 81) had no effect on HeLa cell growth (**Figures 2 and 3**).

Therefore, no antisense TS oligodeoxynucleotides targeted to the translation start site 5 were successful in inhibiting growth of two different human tumour cell lines (human breast carcinoma MCF-7 cells or human cervical carcinoma HeLa cells). **Two separate antisense TS oligodeoxynucleotides targeted to the 3' end of the TS gene were potent inhibitors of human tumour cell growth.**

10 **Example 1.3:**

(a) Antisense oligodeoxynucleotide targeting of the thymidylate synthase translation stop site as a method to enhance human tumour cell sensitivity to the toxic effects of Tomudex (ZD 1694).

15

Antisense TS oligodeoxynucleotides (oligos 86 and 83) targeting sequences in the 3' untranslated region of TS mRNA enhanced human cervical carcinoma cell sensitivity to Tomudex. The enhancement in sensitivity was in addition to the directly cytostatic effects of oligos 86 and 83 (**Figures 4 and 5**).

20

(b) Antisense oligodeoxynucleotide targeting of the thymidylate synthase translation start site as a method to enhance human cell resistance to the toxic effects of Tomudex (ZD 1694).

25

An antisense TS oligodeoxynucleotide (oligo 91) targeting the translation start site of TS mRNA enhanced human cervical carcinoma cell resistance to the toxic effects of Tomudex (**Figure 4**).

Example 1.4: Induction of transcription of genes targeted with antisense nucleic acids as a screening method to identify appropriate target sequences for antisense nucleic acids.

Human tumour cells appear to compensate for antisense inactivation of specific mRNA by increasing transcription of genes producing the target sequences, a process that can be termed "compensatory transcription", resulting in resistance to the effectiveness of antisense nucleic acids. It has been observed, that TS gene transcription is induced in human MCF-7 breast carcinoma cells by treatment with antisense TS RNA and oligodeoxynucleotides targeted to regions at or near the TS mRNA translation start site. The same phenomenon has been observed in human HeLa cells transiently-transfected with antisense TS oligo 91 (targeted to the translation start site), but not in response to oligo 86 (targeted to the translation stop site) (Figure 6). Increased specific gene transcription in response to transfected antisense nucleic acids would indicate that the target sequence is inappropriate to achieve downregulated gene expression. On the other hand, it may be an appropriate sequence to target to achieve upregulated gene expression (to increase resistance to chemotherapeutic drugs, for example, in normal tissues).

In summary, the present invention has demonstrated that antisense oligonucleotides, targeted against selected regions of thymidylate synthase mRNA, can effectively inhibit growth

when administered alone. They can also enhance cell killing by Tomudex. Conversely, antisense oligonucleotides targeted to certain mRNA regions (for example, the translation start site) may either be ineffective, or enhance growth and survival during exposure to Tomudex. Ineffectiveness may be due to oligonucleotide-induced TS gene transcription. It is essential to identify TS mRNA regions that may be effectively targeted with antisense sequences to inhibit tumour cell growth and enhance the toxicity of anticancer drugs. Furthermore, the mechanism by which antisense sequences targeted to 5' TS mRNA regions induce TS gene transcription has important implications for choosing antisense targets in TS mRNA in particular, and for optimising antisense strategies in general.

References

Almendral, J.M., *et al.* Mol. Cell. Biol. 8:2140-2148, 1988.

Ayusawa, D., *et al.* J. Mol. Biol. 190:559-567, 1986.

5 Behrend, E.I., *et al.* Cancer Res. 54:832-837, 1994.

Calvert, A.H., *et al.* J. Clin. Oncol. 4:1245-1252, 1986.

Chu, E., *et al.* Proc. Natl. Acad. Sci. USA 88:8977-8981, 1991.

Chu, E., *et al.* Mol. Pharm. 43:527-533, 1993a.

Chu, E., *et al.* Mol. Cell. Biol. 15:179-185, 1995.

10 Chu, E., *et al.* Mol. Cell. Biol. 14:207-213, 1994.

Chu, E., *et al.* Proc. Natl. Acad. Sci. USA 90:517-521, 1993b.

Chu, E., *et al.* Cancer Res. 50:5834-5840, 1990.

Church, G.M., *et al.* Proc. Natl. Acad. Sci. USA 81:1991-1995, 1984.

Danenberg, P.V., Biochim. Biophys. Acta 473:73-92, 1977.

15 DeGregori, J., *et al.* Mol. Cell. Biol. 15:4215-4224, 1995.

Denhardt, D.T., *et al.* Oncogene 2:55-59, 1988.

Farnham, P.J., *et al.* Biochim. Biophys. Acta Rev. Cancer 1155:125-131, 1993.

Hardy, L.W., *et al.* Science 235:448-455, 1987.

Heidelberger, C., *et al.* Adv. Enzymol. 54:58-119, 1983.

20 Jackman, A.L., *et al.* Adv. Enzyme Regul. 31:13-27, 1991a.

Jackman, A.L., *et al.* Cancer Res. 51:5579-5586, 1991b.

Jelinek, W.R., *et al.* Proc. Natl. Acad. Sci. USA 77:1398-1402, 1980.

Jenh, C.-H., *et al.* Mol. Cell. Biol. 5:2527-2532, 1985.

Johnson, L.F. *et al.* J. Cell. Biochem. 54:387-392, 1994.

25 Karin, M., *et al.* Nucleic Acids Res. 10:3165-3173, 1982.

Keyomarsi, K., *et al.* J. Biol. Chem. 268:15142-15149, 1993.

Kikuchi, K., *et al.* J. Biol. Chem. 267:21505-21511, 1992.

Koropatnick, J., *et al.* Proc. Soc. Exp. Biol. Med. 188:287-300, 1988.

Koropatnick, J., *et al.* BioTechniques 22:64-66, 1997.

30 Koropatnick, J., *et al.* Mol. Biol. Med. 5:69-83, 1988.

Lochshin, A., Proc. Natl. Acad. Sci. USA 76:750-754, 1979.

Maley, F., *et al.* J. Biol. Chem. 235:2968-2970, 1960.

Marzluff, W.F., *et al.* IRL Press, Oxford, 89-129, 1984.

McKay, R.A., *et al.* Nucleic Acids. Res. 24:411-417, 1996.

Mudrak, I., *et al.* Mol. Cell. Biol. 14:1886-1892, 1994.

Navalgund, L.G., *et al.* J. Biol. Chem. 255:7386-7390, 1980.

5 Peters, G.J., *et al.* Cancer Res. 46:20-28, 1986.

Peters, G.J., *et al.* Eur. J. Cancer 30A:1408-1411, 1994.

Rapaport, E., *et al.* Proc. Natl Acad. Sci. USA 89:8577-8580, 1992.

Sambrook, J., *et al.* T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.


10 Suzuki, M., *et al.* Oncology 51:334-338, 1994.

Takeishi, K., *et al.* Nucleic Acids Res. 13:2035-2043, 1985.

Voeller, D.M., *et al.* Nucleic Acids Res. 23:869-875, 1995.

Volm, M., *et al.* Anticancer Res. 12:2293-2296, 1992.

Volm, M., *et al.* Anticancer Res. 14:1271-1276, 1994.



Figures

1/7





Figure 1: MCF-7 cell growth is inhibited by transfection with antisense TS oligo 86 (targeted to the translation stop site), but is enhanced by transfection with antisense TS oligos 90 or 92 (targeted to sequences at or near the translation start site).

Cells were transiently-transfected with 0.5 or 1.0 μM antisense TS oligonucleotides in Lipofectin as described. Cell numbers were measured by Coulter counter in triplicate flasks after 4 days of growth. Control cells were treated with Lipofectin without oligonucleotides.

Cell growth is expressed as a percentage of growth of control cells.

*: Significantly higher than control ($p<0.05$, one way analysis of variants).

**: Significantly lower than control ($p<0.05$, one way analysis of variants).



Figures

2/7




Figure 2: HeLa cell growth is inhibited by transfection with antisense TS oligo 86 (targeted to the translation stop site), but is enhanced after transfection with antisense TS oligo 91 (targeted to the translation start site).

HeLa cells were transfected with 0.05 or 0.10 μ M antisense TS oligonucleotides in Lipofectin (10 μ g/ml) for 4 hours as described. Note that oligo concentrations are considerably lower than those used for MCF-7 cells. The efficiency of Lipofectin-mediated DNA transfection of HeLa cells is greater than for MCF-7 cells. Lipofectin was removed, the cells were trypsinised, and 25,000 viable cells per flask were plated in tissue culture flasks. Cell numbers were measured by Coulter counter in triplicate flasks after 4, 7 and 8 days of growth. Control cells were treated with Lipofectin without oligonucleotides. Cell growth is expressed as a percentage of growth of control cells.

*: Significantly higher than control ($p < 0.05$, Student's t-test).

**: Significantly lower than control (Student's t-test).



Figures

3/7





Figure 3: HeLa cell growth is inhibited by transfection with antisense TS oligo 83 (targeted to a 3' untranslated sequence downstream of the translation stop site), but is not affected by transfection with antisense TS oligo 81 (targeted to the translation start site).

The experimental protocol was as described in the legend to Figure 2.



Figures

4/7





Figure 4: Transient transfection of HeLa cells with oligo 86 (targeted to the TS translation stop site) enhances sensitivity to Tomudex. Oligo 91 (targeted to the TS translation start site) reduces sensitivity to Tomudex.

HeLa cells were transfected with 0.05 and 0.10 μ M antisense TS oligonucleotides and plated in flasks at low density, as described for Figure 2. Tomudex (0-8 nM) was added (triplicate flasks for each Tomudex concentration) and the cells allowed to proliferate for 7 days. Cell numbers were measured by Coulter counting at that time. Survival is plotted as a percentage of growth in cells transfected with oligonucleotide, but untreated with Tomudex. Therefore, these data reveal inhibition or enhancement of Tomudex killing independent of growth inhibition or enhancement induced by oligonucleotides in the absence of Tomudex. The mean of three values is plotted. Error bars were smaller than the size of the symbol in each case.

*: Significantly different from control ($p < 0.05$, Student's t-test).



Figures

5/7





Figure 5: Transient transfection of HeLa cells with oligo 83 (targeted to a sequence in the 3' untranslated region of TS mRNA) enhances sensitivity to Tomudex. Oligo 81 (targeted to a 3' sequence downstream of that targeted by oligo 81) has no effect on Tomudex sensitivity.

HeLa cells were transfected with 0.10 μM antisense TS oligonucleotides and plated in flasks at low density, as described for Figure 2. Tomudex (0-10 nM) was added (triplicate flasks for each Tomudex concentration) and the cells allowed to proliferate for 4 days. Cell numbers were measured by Coulter counting at that time. Survival is plotted as a percentage of growth in cells transfected with oligonucleotide, but untreated with Tomudex. Therefore, these data reveal enhancement of Tomudex killing independent of growth inhibition induced by oligonucleotides in the absence of Tomudex. The mean of three values is plotted. Error bars were smaller than the size of the symbol in each case.

*: Significantly different from control ($p < 0.05$, Student's t-test).



Figures

6/7




Figure 6: Antisense TS oligo 91, but not oligo 86, stimulates TS gene transcription in human HeLa cells.

The same HeLa cells for which data are presented in Figure 2 were assessed for run-on transcription of TS, glyceraldehyde phosphate dehydrogenase (GAPDH), and 18S rRNA genes. Briefly, cells were transfected with 0.05 and 0.10 μM antisense TS oligonucleotides in Lipofectin (10 μg/ml), or with Lipofectin alone (LFA control) for 4 hours as described in the progress report. Lipofectin was removed and cells were trypsinised and replated in tissue culture flasks. Four days after transfection, nuclei were isolated from approximately 5×10^6 cells for each treatment and initiated TS, GAPDH, and 18S rRNA transcripts allowed to incorporate [32 P]-CTP for 30 minutes. Alcohol-precipitable radiolabeled RNA was hybridised for 48 hours to unlabeled TS, GAPDH, and 18S rRNA cDNA immobilised in triplicate dots on nylon membrane as described. Relative transcription rate is presented as:

$$\text{Relative transcription rate} = \frac{\text{(hybridisation signal from gene of interest)}}{\text{(hybridisation signal for GAPDH or 18S rRNA genes)}}$$



Figures

7/7

(first 80 bases in TS mRNA not shown)




Figure 7: Human mRNA for thymidylate synthase (EC 2.1.1.45), bases 1 to 1536.

CJC/BST/97-070

16OCT97DB

PCT | eB 98 | 02820

14.9.98

Zonera